Buscar
Mostrando ítems 1-1 de 1
Eficacia y seguridad del biosimilar ABP 501 (Adalimumab) comparado con biosimilar CT-P13 (Infliximab) en pacientes adultos con artritis reumatoide. Revisión sistemática
Introduction: There is no scientific evidence of comparative studies between biosimilars that demonstrate safety and efficacy, this being relevant for clinicians and insurers to feel supported at the time of acquiring and ...